Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC

Recruiting now · Not applicable

Conditions studied: Diabetic Foot Ulcer, Venous Leg Ulcer

In brief

The purpose of this study is to compare Pellograft to standard of care modalities in treating diabetic foot ulcers in human subjects, and to compare Sanograft to standard of care in treating venous leg ulcers. The study will demonstrate wound healing outcomes with comparators including time to wound epithelialization, decrease in wound size, and total number of study product applications towards healing outcome. This information is important to the Centers for Medicare and Medicaid Services (CMS) and other payors in determining coverage policy and reimbursement for this product category.

Key facts

Study ID

NCT06515093

Run by

Surgenex

People needed

180

Starts

2024-06-23

Expected to finish

2027-09-08

Last updated by the study team

2026-04-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is at least 18 years of age
• Diabetic Foot Ulcer Only - Subject has diagnosed Type 1 or Type 2 diabetes
• Subject's wound is located on foot or ankle (DFU) or leg (VLU)
• Subject has diabetic foot ulcer > 1.0 cm2 and ≤ 25 cm2 OR venous leg ulcer > 1.0 cm2 and ≤ 50 cm2
• Subject has adequate circulation to affected extremity with TcPO2 results of ≥ 40 mm Hg on the dorsum of the affected foot or ABI results ≥ 0.7 and≤ 1.2 or Great Toe Pressure ≥ 50 mmHg
• Subject is willing and able to comply with all protocol requirements
• Subject is willing and able to provide informed consent or obtain consent from legal authorized representative (LAR)

You may not qualify if…

• Subject is pregnant
• Subject with diagnosed diabetes has HbA1C > 12 within 3 months Prior to randomization
• Subject has > 30% reduction in wound size after 2-week run-in period
• Subject has active infection, undrained abscess, or critical colonization of the wound with bacteria
• Subject has osteomyelitis or joint capsule on investigator's exam or radiographic evidence or bone culture, histology, x-ray changes or MRI
• Subject is on parenteral corticosteroids or any cytotoxic agents for 7 consecutive days during 30 days before screening. Chronic oral steroid use is not excluded if dose < 10 mg per day of prednisone
• Subject is currently undergoing cancer treatment
• Subject has used biologic skin substitutes within 14 days of enrollment
• Subject has an allergy to suture material
• Subject has life expectancy less than six-months as assessed by the investigator
• Subject is participating in another clinical research study prior to this study completion

Where it is running

• ILD Research — Vista, California, United States (enrolling)
• Tulsa Wound Center — Tulsa, Oklahoma, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.